Official notifications will be sent out to late-breaking science and ongoing clinical trials abstract submitters on Dec. 2. Please make certain that your e-mail settings allow e-mails from AHAISC@abstractsonline.com.

Late-Breaking Science Abstract Categories and Definitions

Late-Breaking Science and Ongoing Clinical Trials Abstract Submission Guidelines

Rules for Abstract Submission:
Criteria
Acceptance
Presentation
Author Name(s)
Data
Withdrawal
Title
Text
Revisions
Copyright Transfer Agreement
U.S. Government Employee Author

Criteria

Ongoing Clinical Trials Abstract Criteria

1. Ongoing Clinical Trials Abstracts Submission is for rationale and design descriptions and eligibility and recruitment updates for clinical trials or large ongoing multicenter registries.
   
   
2. Interim analyses are not eligible for OGCT and should be submitted to the appropriate category in Late-Breaking Science if applicable. (Please see the criteria for Late-Breaking Science Abstract Submission below.)
   
   
3. Any abstract submitted as an Ongoing Clinical Trial Abstract that does not fit the criteria above should not be submitted in this category and will not be considered for inclusion in the ISC 2010 program.
   

Late-Breaking Science Abstract Criteria

1. Late-Breaking Science abstracts should impact future stroke care and treatment. The abstract should focus on unusually important results obtained since the Aug. 10 scientific abstract deadline.
   
   
2. You must submit an accompanying letter with your abstract; this accompanying letter should ONLY explain why the data was not available prior to the regular submission deadline. This statement must not exceed 100 words.  
   
   
3. If the presenter of the late-breaking abstract has been selected to participate in an invited symposium where this topic will be covered, they are not eligible to submit a late-breaking abstract.
   

Acceptance

1. Late-Breaking Science accepted abstracts (both oral and poster presentations) cannot be published prior to date and time of presentation and may not be presented at any national or international meeting held prior to Feb. 26, 2010. Any data contained is embargoed for release at the date and time of presentation or time of AHA news event and no information may be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation.
   
   
2. Accepted abstracts cannot be presented at any national or international meeting held prior to Feb. 26, 2010. Any data contained is embargoed for release at the date and time of presentation or time of AHA news event and no information may be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation.
   
   
3. Abstract grading is blinded. Abstracts are selected on the basis of scientific merit. Late-Breaking Science abstracts are allocated to oral or poster presentations. Ongoing Clinical Trials abstracts are allocated to poster presentations only.
   
   
4. Guidelines for presentations will be provided to authors of accepted abstracts.
   
   
5. Abstract acceptance/non-acceptance status will be available on this Web site and e-mailed in mid-December.
   
   
6. Late-Breaking Science abstracts will not be published. They will be available online on the International Stroke Conference Web site on Feb. 26, 2010, and will be included in the International Stroke Conference’s Abstracts on CD-ROM.
   
   
7. Ongoing Clinical Trials abstracts will not be published. They will be available online on the International Stroke Conference Web site on Feb. 26, 2010, and will be included in the International Stroke Conference’s Abstracts on CD-ROM.
   

Presentation

1. All presentations and question-and-answer sessions will be conducted in English.  Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to help translate.
   
   
2. Submission of an abstract constitutes a commitment by the author(s) to present it if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts.
   
   
3. The American Stroke Association, a division of the American Heart Association, reserves the right to all video or audio recordings of presentations at the International Stroke Conference 2010.
   
   
4. The presenter is responsible for expenses associated with the submission and presentation of an abstract (e.g., registration, airfare, lodging, etc.),
   
   
5. No 35 mm slides are permitted at the conference.
   
   
6. Oral presentations must be in electronic format. Electronic presentations must be submitted at least 12 hours in advance of the session start time. Instructions will be sent to the presenting author in mid-January.
   
   
7. If you are referencing work previously published by another author, please be sure to include a complete citation at the bottom of the appropriate slide.
   
   
8. Recording Policy:
   1. Unauthorized recording of the AHA Scientific Sessions, scientific conferences and the ASA International Stroke Conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.
   2. The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at AHA/ASA scientific conferences and meetings.

Rules for Submission of Abstracts

Author Name(s)

1. If an author's name appears on more than one abstract, it must be identical on each abstract.
   
   
2. The submitting author is designated as the presenting author. You may rearrange the order of the authors; however, the senior author must always be listed last. The presenter must be an author of the abstract.
   
   
3. Additions or deletions of author names will not be permitted after Nov. 2, 2009.

Abstract Data

1. The International Stroke Conference 2010 is a forum for the presentation of novel research findings. Thus, the work covered by the abstract must not have been published (manuscript or abstract) prior to Feb. 26, 2010.
   
   
2. Abstracts accepted for presentation are embargoed for release at the date and time of presentation or time of AHA news event and no information may be released before then.
   
   
3. Late-Breaking Science Abstract Submission:
   
   1. Late-Breaking Science abstracts should impact future stroke care and treatment. The abstract should focus on unusually important results obtained since the Aug. 10 Scientific Abstract deadline.
   2. You must submit an accompanying letter with your abstract; this accompanying letter should ONLY explain why the data was not available prior to the regular submission deadline. This statement must not exceed 100 words.  
   3. If the presenter of the late-breaking abstract has been selected to participate in an invited symposium where this topic will be covered, they are not eligible to submit a late-breaking abstract.
      
      
4. Ongoing Clinical Trials Abstract Submission:
   
   1. Ongoing Clinical Trials Abstracts Submission is for rationale and design descriptions and eligibility and recruitment updates for clinical trials or large ongoing multicenter registries.
   2. Interim analyses are not eligible for OGCT and should be submitted to the appropriate category in Late-Breaking Science if applicable. (Please see the criteria for Late-Breaking Science Abstract Submission above.)
   3. Any abstract submitted as an Ongoing Clinical Trial Abstract that does not fit the criteria above should not be submitted in this category and will not be considered for inclusion in the ISC 2010 program.
      
      
5. Ongoing Clinical Trials abstracts must provide a full description and status reports for ongoing, multicenter or controlled clinical trials. The trials must be recruiting patients/centers or collecting follow-up data at time of presentation. The American Stroke Association encourages submissions for studies that test interventions in all areas of cerebrovascular disease, including prevention, acute treatment and recovery. Abstracts describing ongoing, multicenter, prospective registries of national or international scope will also be considered.
   
   
6. Ongoing Clinical Trials abstracts must include the following information in the body of the abstract:
   
   • Trial Abbreviation
   • Trial Registry Number or ID
   • Background
   • Objective
   • Design
   • Population studied (including sample size)
   • Intervention(s)
   • Outcome Measure(s)
   • Analysis
   • Trial Status
   • PI/Coordinator Name(s)
   • PI/Coordinator Affiliation(s)
   • Trial Sponsor(s)
   • Trial Contact Information (name, e-mail, Web, fax, and/or phone)
   • Trial E-mail
   • Trial Web Site
     
     
7. Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
   
   
8. Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
   
   
9. Because of the large number of submitted abstracts, resubmission of an abstract with revisions and/or edits to an abstract is not permitted after the deadline of Nov. 2, 2009, 5 p.m. CST.
   
   
10. Proofread abstracts carefully to avoid errors before submission. No proof pages will be sent to authors.

Abstract Withdrawal

1. Requests for withdrawal of an abstract must be received in writing no later than Dec. 30, 2009.

Abstract Title

1. An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.

Abstract Text

1. Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
   
   
2. Use generic drug names.
   
   
3. Do not begin sentences with numerals.
   
   
4. Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
   
   
5. Do not include references, credits or grant support.
   
   
6. Do not include the names or personal information of any patient participating in the study or trial.
   
   
7. Late-Breaking Science abstracts are limited to 1,950 characters (about 400 words). This includes title, text and any graphic/table. Addition of a table deducts 250 characters; addition of a graphic deducts 500 characters.
   
   
8. Ongoing Clinical Trials abstracts are limited to 3,500 characters. This includes title, text and any graphic/table. Addition of a table deducts 250 characters; addition of a graphic deducts 500 characters.

Abstract Revisions

1. After the Nov. 2, 2009, 5 p.m. CST deadline, abstracts may not be revised in any way or resubmitted.
   
   
2. Additions or deletions of author names will not be permitted after Nov. 2, 2009, 5 p.m. CST.
   
   
3. Proofread abstracts carefully to avoid errors before submission.

Abstracts Copyright Transfer Agreement

If your abstract is accepted for presentation at the International Stroke Conference 2010, all authors will be asked to sign a copyright transfer agreement stating the following:

The author(s) hereby assigns, conveys, and otherwise transfers all rights, title, interest and copyright ownership in said work to the AHA/ASA effective upon acceptance of said work for publication. “Work” includes the material submitted for publication and any other related material submitted to the AHA/ASA.

The assignment of rights to the AHA/ASA includes, but is not expressly limited to, rights to edit, publish, reproduce, distribute copies, prepare derivate works, include in indexes or search databases in print, electronic, or other media, whether or not in use at the time of execution of this agreement, and claim copyright in said work throughout the world for the full duration of the copyright and any renewals or extensions thereof.

The assignment of rights hereunder does not extend to the full length article on which the abstract is based.

Author(s) retain the right to subsequently include the work in articles, books or derivative works that he/she authors or edits provided said use does not imply the endorsement of the AHA/ASA.  Other uses or reproductions require permission from the AHA/ASA, which shall not be unreasonably withheld.

Author(s) hereby represents and warrants that he/she/they is/are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, and that the work is original and does not infringe upon any copyright, proprietary, or personal right of any third party.

If the AHA/ASA does not publish said work, author(s) will be notified and all rights assigned hereunder will revert to author(s).

If a joint work, all co-authors must transfer rights in said work to the AHA/ASA by executing this Agreement.

This Agreement must be executed as is without revision or substitution of terms. A handwritten signature of the author(s) is required. This Agreement is governed by the laws of the United States of America.

For U.S. Government Employee Author(s):
The author(s) hereby warrants that the above-described work was authored by employees of the United States Government as part of their official duties and therefore may be published and reproduced without restriction.